Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(2)
prifetrastat in combination with fulvestrant
1 trial
phase_2
unicancer
prifetrastat monotherapy for 15 days then combination with fulvestrant
1 trial
phase_2
unicancer
2 unique interventions1 categories

Analytics

Trial Phases

Phase 21

Trial Status

Other1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Research Network

Collaboration Network

2 collaborators·1 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

2 similar investigators found

Fabrice ANDRE, MD

Gustave Roussy, Cancer Campus, Grand Paris

Related
2 trials

Shared therapeutic areas:

Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic settingMetastatic (Stage IV) Melanoma

Worked with same sponsors:

PfizerUNICANCER
Collaborated on 1 trial
Similarity Score24%

Elodie LONG-MIRA, PH

Centre Hospitalier Universitaire de Nice

Related
1 trials

Shared therapeutic areas:

Metastatic (Stage IV) Melanoma
Similarity Score15%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT07340619Phase 2PrincipalInvestigator

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Metastatic (Stage IV) Melanoma
Not Yet Recruiting

All 1 trials loaded